La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Verve Therapeutics Crescita futura
Future criteri di controllo 0/6
Informazioni chiave
-11.6%
Tasso di crescita degli utili
-3.9%
Tasso di crescita dell'EPS
Biotechs crescita degli utili | 30.3% |
Tasso di crescita dei ricavi | -17.9% |
Rendimento futuro del capitale proprio | -82.9% |
Copertura analitica | Good |
Ultimo aggiornamento | 09 Aug 2024 |
Aggiornamenti recenti sulla crescita futura
Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78
Aug 10The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Recent updates
Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78
Aug 10We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
Jul 12Why Verve Therapeutics Deserves A Spot On Your Watchlist
Jun 13Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher
May 14The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Apr 03Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Feb 13Vectoring In On Verve Therapeutics
Jan 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Verve Therapeutics: Cathie Wood Adds To ARKK
Sep 20Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate
Aug 23Verve Therapeutics falls postmarket on $200M stock offering
Jul 20More CRISPR In Human Subjects
Jul 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Verve Therapeutics: Early-Stage Biotech With A Large Market
Apr 16Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans
Jan 31Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing
Aug 24Verve Therapeutics jumps 75% in its first day of trading
Jun 17Previsioni di crescita degli utili e dei ricavi
Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
---|---|---|---|---|---|
12/31/2026 | 8 | -234 | -236 | -263 | 7 |
12/31/2025 | 13 | -261 | -233 | -206 | 9 |
12/31/2024 | 18 | -221 | -209 | -176 | 10 |
6/30/2024 | 21 | -193 | -134 | -130 | N/A |
3/31/2024 | 16 | -197 | -150 | -144 | N/A |
12/31/2023 | 12 | -200 | -159 | -150 | N/A |
9/30/2023 | 8 | -193 | -154 | -142 | N/A |
6/30/2023 | 5 | -192 | -173 | -159 | N/A |
3/31/2023 | 3 | -179 | -152 | -138 | N/A |
12/31/2022 | 2 | -157 | -136 | -122 | N/A |
9/30/2022 | 1 | -148 | -127 | -117 | N/A |
6/30/2022 | N/A | -125 | -117 | -110 | N/A |
3/31/2022 | N/A | -137 | -102 | -96 | N/A |
12/31/2021 | N/A | -120 | -82 | -78 | N/A |
9/30/2021 | N/A | -113 | -69 | -65 | N/A |
6/30/2021 | N/A | -99 | -54 | -50 | N/A |
3/31/2021 | N/A | -53 | -47 | -44 | N/A |
12/31/2020 | N/A | -46 | -39 | -35 | N/A |